Industry collaborations are an important part of Moerae Matrix’s product development strategy. Our management team has built a successful track record in efficiently advancing compounds through research and development. We are currently seeking collaborators with significant clinical development and commercial expertise for our MMI-0100 development programs in pulmonary diseases such as Idiopathic Pulmonary Fibrosis, COPD, asthma and other conditions. Also, we are seeking partners with development and commercialization experience for a topical formulation of MMI-0100 for acute surgical indications, such as: prevention of adhesions, cutaneous scarring and intimal hyperplasia in conjunction with bypass procedures.

Moerae also has a novel platform of formulation and delivery technologies (nanoparticle and polyplex) that can modulate therapeutics directed against intracellular drug targets. Moerae is actively seeking collaboration partners for its polyplex and nanoparticle technologies.